Del Medical Imaging product lines sold to UMG

NewsGuard 100/100 Score

Del Global Technologies Corp. (OTCBB: DGTC) (“Del Global” or “the Company”) and UMG, INC. (“UMG”) have completed the transaction to sell certain assets and the product lines of Del Medical Imaging from Del Global to UMG. The transfer of ownership was finalized on November 24, 2009. The name of the new entity is Del Medical, Inc. and will remain at its current location in Roselle, IL.

“UMG intends to continue to run Del Medical, Inc. as a wholly-owned subsidiary, enhance the existing product line and maintain the collective current channels of distribution. We are proud to bring the Del Medical product lines under the UMG umbrella. We will continue to offer the same quality and reliability of Del Medical products that our customers have come to expect. Please visit us at this years RSNA in the South Hall at Del Booth # 3247 and UMG Booth # 6408.“ says Toufic Lorenzo, President & CEO of UMG.

“We are pleased that we have found a home with UMG for the Del Medical U.S. imaging business that will provide for it to grow and prosper. The transaction does not include our Villa subsidiary in Italy,” said John Quicke, President and CEO of Del Global. He added, “Del Global will now focus its efforts on growing Villa in the international imaging markets and the power supply business through its RFI business unit. The Company’s headquarters will be moved from Chicago to RFI’s facility in Bay Shore, NY.”

Source:

Del Global Technologies Corp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionizing brain tumor treatment: the rise of AI in neuro-oncology